This is Part 2 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. 

 

In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of newly diagnosed advanced endometrial cancer with mismatch repair proficiency (MMRp). The patient is a 66-year-old woman presenting with postmenopausal vaginal bleeding, significant anemia, and moderate back pain. Following surgery, she is diagnosed with a FIGO stage IV grade 3 MMRp endometrioid adenocarcinoma with residual measurable nodal disease.

 

The faculty explore the surgical vs neoadjuvant approach in patients with metastatic disease complicated by active bleeding, and how to select between pembrolizumab and dostarlimab when considering front-line chemo-immunotherapy regimens. They also debate whether immunotherapy should be reserved for the recurrent setting in MMRp patients or used upfront, and discuss the role of emerging clinical trials that aim to improve outcomes in this population through novel antibody-drug conjugate combinations.